Q: What is the primary problem 340BCheck solves?
Covered entities (CEs) face growing 340B compliance risk but lack the tools to keep pace with the ever-changing regulatory environment and volume of auditable transactions. Manual, sample-based audits miss errors, OPAIS records often fall out of sync, and documentation is scattered across systems – leaving organizations exposed to HRSA audit findings, manufacturer disputes, and repayment liabilities. And with the Rebate Pilot taking effect January 2027, every rebate claim becomes a claims-level compliance assertion. 340BCheck solves both problems: providing continuous audit readiness today, while serving as the compliance foundation that makes rebate submissions defensible tomorrow – without requiring increases in staffing.
Key features:
- 100% automated transaction auditing: validates every 340B claim against patient eligibility, provider eligibility, medication eligibility, and location eligibility in real time, replacing manual spot checks entirely
- Centralized compliance dashboard: a simple command center managing all six core HRSA compliance events: internal claims, OPAIS monitoring, contract pharmacy management, Medicare cost report maintenance, Medicaid exclusion file maintenance, and policies and procedures
- Daily OPAIS sync: automatically detects registration mismatches, contract pharmacy changes, and child site updates before they become audit findings
- HRSA mock audit toolkit: built directly from the HRSA Data Request List, enabling full internal audit preparation with instant access to all required reports and documentation
- Rebate-ready infrastructure: In combination with other Bluesight tools, positions CEs for the January 2027 HRSA rebate pilot through 340B/MFP purchasing decision support, 340B/MFP deduplication, and 340B/MFP submission, payment tracking, and total expenditure insights.
Key facts:
- Nearly 200 CEs currently use 340BCheck – spanning DSH hospitals, critical access hospitals, and FQHCs
- In fiscal year 2025, HRSA audited 115 CEs and nearly half had adverse findings; among those using 340BCheck, none had any adverse findings
- The platform is architected directly from the HRSA Data Request List – meaning every workflow, report, and audit output is mapped to what HRSA requires
- 340BCheck is a fully cloud-based SaaS solution requiring no local software, plugins, or on-site infrastructure
- Bluesight employs multiple Apexus-certified 340B experts across product, implementation, and clinical teams who are embedded in every customer engagement – not a separate consulting service
Q: How does 340BCheck improve your clients’ 340B program?
340BCheck shifts CEs from reactive, sample-based compliance to continuous, automated oversight. Audit preparation that typically takes one to two weeks is reduced to under a day. Staff move from manually reviewing transactions to managing only flagged exceptions. OPAIS accuracy is maintained daily rather than episodically. And when an HRSA audit arrives, every required document and data point is already organized and accessible.
With the Rebate Pilot arriving January 2027, 340BCheck also extends beyond compliance – covering claims filing, discount deduplication, and rebate tracking – so CEs are protected on both regulatory and financial fronts.
Q: How is 340BCheck unique?
340BCheck is the only compliance platform built backward from the HRSA Data Request List, meaning every audit, workflow, and report maps precisely to what regulators require, not to what is convenient to build. Unlike TPA-adjacent tools or deduplication point solutions, 340BCheck audits 100% of transactions automatically and manages all six core HRSA compliance events in a single dashboard. As the 340B rebate pilot takes effect in January 2027, 340BCheck supports the full rebate lifecycle – claims filing, discount deduplication, and rebate tracking – making it the only platform built for both today’s compliance program and the upcoming rebate model.
AJ Rivosecchi is Director of Product at Bluesight. He can be reached at aj.rivosecchi@bluesight.com
